Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-018046
Filing Date
2019-05-09
Accepted
2019-05-09 16:31:28
Documents
54
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fprx-10q_20190331.htm 10-Q 1733793
2 EX-10.1 fprx-ex101_30.htm EX-10.1 69935
3 EX-31.1 fprx-ex311_9.htm EX-31.1 8724
4 EX-31.2 fprx-ex312_8.htm EX-31.2 8496
5 EX-32.1 fprx-ex321_7.htm EX-32.1 5333
6 EX-32.2 fprx-ex322_6.htm EX-32.2 5228
7 GRAPHIC goxdcdmeiskg000001.jpg GRAPHIC 35710
  Complete submission text file 0001564590-19-018046.txt   6096095

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT fprx-20190331.xml EX-101.INS 1336178
9 XBRL TAXONOMY EXTENSION SCHEMA fprx-20190331.xsd EX-101.SCH 38783
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fprx-20190331_cal.xml EX-101.CAL 46454
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fprx-20190331_def.xml EX-101.DEF 123317
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20190331_lab.xml EX-101.LAB 343459
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20190331_pre.xml EX-101.PRE 250358
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

EIN.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36070 | Film No.: 19811048
SIC: 2834 Pharmaceutical Preparations